**Chapter 2**

[51] Biancone L et al. Identification of a novel inducible cell-surface ligand of CD5 on activated lymphocytes. The Journal of Experimental Medicine. 1996;

Normal and Malignant B-cell

Topics in Microbiology and Immunology. 2016;393:123-142

[61] Jimenez C, Hernandez C, Pimentel B, Carrera AC. The p85 regulatory subunit controls sequential activation of phosphoinositide 3-kinase by Tyr kinases and Ras. The Journal of Biological Chemistry. 2002;277:

[62] Morbach H et al. CD19 controls Toll-like receptor 9 responses in human B-cells. The Journal of Allergy and Clinical Immunology. 2016;137:

41556-41562

889-898.e6

[52] Noh G, Lee JH. Regulatory B-cells and allergic diseases. Allergy, Asthma & Immunology Research. 2011;3:168-177

[53] Jackson SM, Wilson PC, James JA, Capra JD. Human B-cell subsets. Advances in Immunology. 2008;98:

[54] Yokota A et al. Two species of human Fc epsilon receptor II (Fc epsilon RII/CD23): Tissue-specific and IL-4 specific regulation of gene expression.

[55] Acharya M et al. CD23/FcεRII: Molecular multi-tasking. Clinical and Experimental Immunology. 2010;162:

[56] Ahmed R et al. A public BCR present in a unique dual-receptorexpressing lymphocyte from type 1 diabetes patients encodes a potent T cell autoantigen. Cell. 2019;177:

[57] Corcos D et al. Pre-B-cell

development in the absence of lambda 5 in transgenic mice expressing a heavychain disease protein. Current Biology.

[58] Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;

[59] Inabe K, Kurosaki T. Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood. 2002;99:584-589

[60] Okkenhaug K, Burger JA. PI3K signaling in normal B-cells and chronic lymphocytic leukemia (CLL). Current

Cell. 1988;55:611-618

184:811-819

151-224

12-23

1583-1599.e16

1995;5:1140-1148

120:1175-1184

22
